ABSTRACT
Hepatitis-E virus (HEV), an etiologic agent of acute inflammatory liver disease, is a significant cause of morbidity and mortality in South Asia. HEV is considered endemic in Nepal; but data on population-level infection transmission is sparse. We conducted a representative longitudinal serologic study between February 2019 and April 2021 in urban and peri-urban areas of central Nepal to characterize community-level HEV transmission. Individuals were followed up to four times, during which capillary blood samples were collected on dried blood spots and tested for anti-HEV immunoglobulin-G antibodies. Analyzing 2513 dried blood samples from 923 participants aged 0-25 years, we found a seroprevalence of 4.8% and a seroincidence rate of 10.9 per 1000 person-years. Notably, young adults, including women of childbearing age, faced the highest incidence of infection. Geospatial analysis identified potential HEV clusters in Kavre and Kathmandu districts, emphasizing the need for targeted interventions. Water source played a crucial role in HEV transmission, with individuals consuming surface water facing the highest risk of seroconversion. Our findings underscore the endemic nature of HEV in Nepal, emphasizing the importance of safe water practices and potential vaccination strategies for high-risk groups.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was reviewed and approved by the Nepal Health Research Council and Ethics Review Board of Dhulikhel Hospital and Stanford University.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript.
